
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Platinum doublet chemotherapy
Selpercatinib (TA760)
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
Docetaxel
Selpercatinib (TA760)
Docetaxel
Selpercatinib (TA760)
Docetaxel
Selpercatinib (TA760)
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
Selpercatinib (TA760)
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
Docetaxel
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
Docetaxel
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
Pembrolizumab and carboplatin and paclitaxel (TA770)
Docetaxel
Selpercatinib (TA760)
Selpercatinib (TA760)
Docetaxel
Selpercatinib (TA911)
Platinum doublet chemotherapy
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
Docetaxel
Docetaxel
Pembrolizumab (if PD-L1 >1%) (TA428)
Atezolizumab (any PD-L1 0-100%) (TA520)
Nivolumab (any PD-L1 0-100%) (TA655)
RET fusion positive
PD-L1 <50%
Cancer Drugs Fund
TA000
Disease progression
NHSE policy